- Home
- MRNA vs RNR Comparison
MRNA vs RNR Comparison
Compare MRNA & RNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MRNA | RNR |
|---|---|---|
| Founded | 2010 | 1993 |
| Country | United States | Bermuda |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Property-Casualty Insurers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.3B | 12.3B |
| IPO Year | 2018 | 1995 |
Fundamental Metrics
Financial Performance| Metric | MRNA | RNR |
|---|---|---|
| Price | $27.57 | $266.10 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 13 | 13 |
| Target Price | $33.91 | ★ $291.73 |
| AVG Volume (30 Days) | ★ 9.9M | 387.6K |
| Earning Date | 11-06-2025 | 10-28-2025 |
| Dividend Yield | N/A | ★ 0.60% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 34.70 |
| Revenue | $2,232,000,000.00 | ★ $12,214,870,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $0.77 | N/A |
| P/E Ratio | ★ N/A | $7.63 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $22.28 | $219.00 |
| 52 Week High | $48.92 | $290.78 |
Technical Indicators
Market Signals| Indicator | MRNA | RNR |
|---|---|---|
| Relative Strength Index (RSI) | 60.85 | 54.79 |
| Support Level | $23.92 | $261.38 |
| Resistance Level | $26.00 | $263.87 |
| Average True Range (ATR) | 1.29 | 5.15 |
| MACD | 0.32 | 0.09 |
| Stochastic Oscillator | 99.82 | 64.18 |
Price Performance
Historical ComparisonAbout MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
About RNR RenaissanceRe Holdings Ltd.
RenaissanceRe Holdings Ltd provides reinsurance and insurance solutions and related services. The company's core products include property, casualty and specialty reinsurance. Revenue is derived from three sources: net premiums earned from the insurance and insurance products sold; net investment income from the investment of capital funds and cash; and other income from the company's joint ventures, advisory services, and other items. The reportable segments of the company are the Property segment which includes catastrophe and other property reinsurance, and the Casualty and Specialty segment which is comprised of casualty and specialty reinsurance. It derives a majority of its revenue from the Casualty and specialty segment.